Historical overview of research into the etiology of hepatocellular carcinoma

  • Toshitsugu Oda


Whether hepatocellular carcinoma (HCC) can be induced by viruses or not is a recent area of study in the field of molecular biomedicine and also a medical issue of worldwide concern. In Japan, cancer claims the life of 190,000 people a year and now ranks as the number one cause of death. Deaths from the disease have recently exceeded the figures for circulatory diseases, which kill more than 140,000 annually. We have overcome diseases caused by bacteria one after the other, with tuberculosis as a most recent example, and as a result during these past decades, our average life span has been extended significantly. In parallel with this extended longevity, cancer and circulatory diseases have begun to draw general attention today.


Liver Cancer Primary Liver Cancer Circulatory Disease Liver Cancer Study Group Australia Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Amano S, Yamamoto H (1960) Infectious hepatitis and cirrhosis as its sequela in Japan. Annual Report of the Institute for Virus Research, Kyoto University 3: 185–334Google Scholar
  2. 2.
    Sheldon WH, James DF (1948) Cirrhosis following infectious hepatitis. A report of five cases, in two of which there were superimposed primary liver cell carcinoma. Arch Intern Med 81: 666–689CrossRefGoogle Scholar
  3. 3.
    Walsche JW, Wolffe HH (1952) Primary carcinoma of the liver following viral hepatitis. Report of two cases. Lancet 2: 1007–1010CrossRefGoogle Scholar
  4. 4.
    WHO report: Viral hepatitis. (1973) WHO Tech Rep Ser No. 512Google Scholar
  5. 5.
    Nishioka K, Hirayama T, Sekine T, Okochi K, Marumi M, Sung J-L, Liu C-H, Lin T-M (1973) Australia antigen and HCC. Gann Monograph Cancer Research 14: 167–175Google Scholar
  6. 6.
    Nishioka K, Levin A, Simons MJ (1975) Hepatitis B antigen, antigen subtypes, and hepatitis B antibody in normal subjects and patients with liver disease. Result of collaborative study. Bull. WHO 52: 293–300PubMedGoogle Scholar
  7. 7.
    Nishioka K (1978) Hepatocellular carcinoma and hepatitis B virus. In: Oda T (ed) Hepatitis Virus. Tokyo University Press, Tokyo, pp 247–255Google Scholar
  8. 8.
    Obayashi A, Okochi K, Marumi M (1972) Familial clustering of asymptomatic carriers of Australia antigen and patients with chronic liver disease or primary liver cancer. Gastroenterology 62: 618–625PubMedGoogle Scholar
  9. 9.
    Shikata T, Uzawa T, Yoshihara N, Akatsuka T, Yamazaki S (1974) Staining methods for Australia antigen in paraffin section. Jap J Exp Med 44: 25–36PubMedGoogle Scholar
  10. 10.
    Assaad F (1985) Global overview of hepatitis B vaccine, WHO-WPR, 3rd Task Force Meeting on Hepatitis BGoogle Scholar
  11. 11.
    The Liver Cancer Study Group of Japan (1984) Primary liver cancer in Japan. Cancer 54: 1747–1755CrossRefGoogle Scholar
  12. 12.
    Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, Tsuji T, Yano M, Kuo G, Choo Q-L, Houghton M, Oda T (1991) A high prevalence of antibody to the hepatitis C virus in patients with HCC in Japan. Cancer 67: 429–433PubMedCrossRefGoogle Scholar
  13. 13.
    Kim C, Koike K, Saito I, Miyamura T, Jay G Nature 351:317–320, 1991 HB-X gene of hepatitis B virus induces hepatic carcinoma in transgenic mouse. NaturePubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1992

Authors and Affiliations

  • Toshitsugu Oda
    • 1
  1. 1.Japanese Red Cross Medical CenterTokyoJapan

Personalised recommendations